The company's lead drug candidate, BO-112, is a best-in-class RNA-based therapy that initiates a powerful immune response to turn 'cold' tumors 'hot' and visible to the immune system, potentially rescuing patients resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in clinical trials as a monotherapy and in combination with checkpoint inhibitors. Highlight Therapeutics collaborates with external partners, including Merck & Co and UCLA, in addition to conducting in-house research.